These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 7671251

  • 1. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
    Smans KA, Hoylaerts MF, Narisawa S, Millán JL, De Broe ME.
    Cancer Res; 1995 Oct 01; 55(19):4383-90. PubMed ID: 7671251
    [Abstract] [Full Text] [Related]

  • 2. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 4. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C, Dean PA, Nelson H.
    Cancer Res; 1994 May 15; 54(10):2738-43. PubMed ID: 8168104
    [Abstract] [Full Text] [Related]

  • 5. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ, Hillstrom JR.
    J Immunol; 1991 Dec 01; 147(11):4035-44. PubMed ID: 1834746
    [Abstract] [Full Text] [Related]

  • 6. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P.
    J Immunol; 1997 Apr 15; 158(8):3965-70. PubMed ID: 9103467
    [Abstract] [Full Text] [Related]

  • 7. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG.
    Cancer; 2004 Mar 01; 100(5):1095-103. PubMed ID: 14983507
    [Abstract] [Full Text] [Related]

  • 8. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 9. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995 Jun 01; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 11. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J, Demanet C, Moser M, Leo O, Thielemans K.
    J Immunol; 1991 Dec 01; 147(11):4019-26. PubMed ID: 1940384
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Dec 01; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.
    Cancer Res; 2007 Apr 15; 67(8):3927-35. PubMed ID: 17440108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.